Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Bell

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumabLee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
JAMA Network Open|May 31, 2023
Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus StatementPui Y Lee, Brad A Davidson, Roshini S Abraham, et al.
Journal of Neonatal-Perinatal Medicine|October 22, 2025
Proceedings of the 15<sup>th</sup> International Newborn Brain Conference: Fetal and/or neonatal brain development, both normal and abnormal: Fota Island, Cork, Ireland, February 28<sup>th</sup> - March 2<sup>nd</sup> 2024Khadar Abdi, Eleri Adams, Sonika Agarwal, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumabLee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
JAMA Network Open|May 31, 2023
Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus StatementPui Y Lee, Brad A Davidson, Roshini S Abraham, et al.
Journal of Neonatal-Perinatal Medicine|October 22, 2025
Proceedings of the 15<sup>th</sup> International Newborn Brain Conference: Fetal and/or neonatal brain development, both normal and abnormal: Fota Island, Cork, Ireland, February 28<sup>th</sup> - March 2<sup>nd</sup> 2024Khadar Abdi, Eleri Adams, Sonika Agarwal, et al.
Pageof 5